Anticancer agent 54

Cat. No.: HY-146063: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Anticancer agent 54 is a potent anticancer agent. Anticancer agent 54 shows antiproliferative activity. Anticancer agent 54 induces apoptosis and cell cycle arrest at G0/G1 phases. Anticancer agent 54 shows anticancer activity depends on DNA intercalation and ROS generation.

For research use only. We do not sell to patients.

Anticancer agent 54 Chemical Structure

CAS No. : 2933882-99-4

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.75 μM Compound: Table 1, R1C1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
HCT-116	IC₅₀	0.27 μM Compound: Table 1, R1C1	Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	0.039 μM Compound: Table 1, R1C1	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of CuSO4 by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of CuSO4 by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	0.04 μM Compound: Table 1, R1C1	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	1 μM Compound: Table 1, R1C1	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of FeSO4 by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of FeSO4 by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	1 μM Compound: Table 1, R1C1	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of FeCl3 by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of FeCl3 by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	1 μM Compound: Table 1, R1C1	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of CdSO4 by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of CdSO4 by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	1 μM Compound: Table 1, R1C1	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of ZnCl2 by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs in presence of ZnCl2 by MTS assay	[PMID: 31962262]
NHDF	IC₅₀	20.83 μM Compound: Table 1, R1C1	Cytotoxicity against human NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
PANC-1	IC₅₀	0.44 μM Compound: Table 1, R1C1	Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
U-251	IC₅₀	0.14 μM Compound: Table 1, R1C1	Antiproliferative activity against human U251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human U251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]

In Vitro

Anticancer agent 54 (compound L) (0-25 µM; 72 h) shows antiproliferative activity with IC₅₀s of 0.04, 0.44, 0.27, 0.14, 0.75, 20.83 µM for MCF-7, PANC-1, HCT116, U-251, A549, NHDF (normal human fifibroblast) clls, respectively^[1].
Anticancer agent 54 (1, 2.5, 5 µM; 24 h) induces cell cycle arrest at G0/G1 phases and apoptosis in a concentration-dependent manner^[1].
Anticancer agent 54 (1 µM; 24 h) increases the reactive oxygen species (ROS) level^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	MCF-7 cells
Concentration:	1, 2.5, 5 µM
Incubation Time:	24 h
Result:	Induced cell cycle arrest at G0/G1 phases in a concentration-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	MCF-7 cells
Concentration:	1, 2.5, 5 µM
Incubation Time:	24 h
Result:	The level of the apoptotic cells increased from 7.62% to 29.33% and the population of living cells decreased from 92.01% to 55.27% at 5 µM.

Molecular Weight

516.68

Formula

C₃₃H₃₆N₆

CAS No.

2933882-99-4

SMILES

CCCCCCCCCCN1C=C(N=N1)C2=CC=C(C=C2)C3=CC(C4=NC=CC=C4)=NC(C5=CC=CC=N5)=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Malarz K,et al.Anticancer activity of 4'-phenyl-2,2':6',2″-terpyridines - behind the metal complexation. Eur J Med Chem. 2020 Mar 1;189:112039. [Content Brief]